Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA approves...

    FDA approves intravenous version of Tesaro drug for chemotherapy nausea

    Written by Ruby Khatun Khatun Published On 2017-10-28T09:44:39+05:30  |  Updated On 18 Aug 2021 3:43 PM IST

    Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.



    The intravenous version of the already-approved drug, Varubi, will be used in combination with other agents to prevent delayed nausea and vomiting associated with some forms of chemotherapy, the company said in a statement.

    The oral version of Varubi was approved by the FDA in 2015.


    The intravenous formulation will be launched in November and cost less than the oral drug, Tesaro's chief executive, Lonnie Moulder, told Reuters in an interview.


    It will have a list price of $295 per ready-to-use vial, compared to $561.80 for the oral drug, Moulder said.


    Chemotherapy-induced nausea and vomiting is considered one of the most acute side effects of cancer therapy and affects up to 80 percent of patients, according to the National Institute of Health.


    Varubi works by blocking the activation of neurokinin (NK)-1 receptors in the nervous system that play an important role in nausea and vomiting.


    Other FDA-approved (NK)-1 receptor antagonist drugs to treat chemotherapy-induced nausea and vomiting include Merck & Co Inc's Emend, which had sales of $549 million last year.


    Tesaro licensed Varubi from Opko Health Inc in December 2010.




    (Reporting by Divya Grover in Bengaluru; Additional reporting by Ismail Shakil in Bengaluru; Editing by Savio D'Souza and Leslie Adler)



    ApprovescancerchemotherapydrugFDAintravenous versionLonnie MoulderNational Institute of Healthnauseapharma newsTesaroU.S. Food and Drug AdministrationVarubi
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok